Changes in treatment plans did not reach statistical significance for newly diagnosis of Prostate and pre-radical surgery group (P = 0.222,P= 0.151).<h4>Conclusion</h4>PSMA PET/CT significantly impacts cTNM staging assessment and treatment decisions in prostate cancer, offering precise evaluation and auxiliary diagnosis. This evidence concerns the gene FOLH1 and prostate carcinoma.